BMS claims first EU okay for adjuvant oesophageal cancer immunotherapyBristol-Myers Squibb is in a battle with Merck & Co for position in the upper gastrointestinal cancer immunotherapy Share XBMS claims first EU okay for adjuvant oesophageal cancer immunotherapyhttps://pharmaphorum.com/news/bms-claims-eu-okay-for-opdivo-in-adjuvant-oesophageal-cancer/
ASCO21: Lynparza aces adjuvant breast cancer therapy trialAstraZeneca and Merck & Co’s Lynparza is primed for even wider use in the treatment of breast cancer Share XASCO21: Lynparza aces adjuvant breast cancer therapy trialhttps://pharmaphorum.com/news/asco21-lynparza-aces-adjuvant-breast-cancer-therapy-trial/
Filing beckons as Lynparza hits the mark in adjuvant breast cancerAstraZeneca’s PARP inhibitor Lynparza has shown a clinical benefit when given as an adjuvant for early breast cancer, Share XFiling beckons as Lynparza hits the mark in adjuvant breast cancerhttps://pharmaphorum.com/news/filing-beckons-as-lynparza-hits-the-mark-in-adjuvant-breast-cancer/
Ibrance trial failure dashes Pfizer’s growth hopes for the drugPfizer already makes big revenues from its breast cancer drug Ibrance, but a late-stage trial failure has set Share XIbrance trial failure dashes Pfizer’s growth hopes for the drughttps://pharmaphorum.com/news/ibrance-trial-failure-dashes-pfizers-growth-hopes-for-the-drug/
GSK to produce a billion doses of COVID-19 vaccine booster by 2021GlaxoSmithKline is to scale up production of its COVID-19 vaccine booster to a billion doses by 2021 to support development of Share XGSK to produce a billion doses of COVID-19 vaccine booster by 2021https://pharmaphorum.com/news/gsk-to-produce-a-billion-doses-of-covid-19-vaccine-booster-by-2021/
